The Patient Recruiting Agency, LLC Announces Enrollment Launched for the CTP-543 THRIVE Clinical Program Investigating Oral Treatment for Moderate to Severe Alopecia Areata

--The CTP-543 THRIVE Clinical Program Is Designed To Evaluate the Hair Regrowth Potential in People With At Least 50% Scalp Hair Loss Due To Alopecia Areata--

AUSTIN, Texas--()--The Patient Recruiting Agency™ announces open enrollment for the THRIVE Clinical Program, a series of clinical trials exploring the investigational product CTP-543 for the potential oral treatment of moderate to severe alopecia areata. CTP-543 is being developed by Concert Pharmaceuticals, Inc.

The purpose of the ongoing THRIVE Clinical Program is to measure the effect of CTP-543 on hair regrowth and to evaluate safety in people with alopecia areata. The THRIVE Clinical Program is now enrolling adults 18 to 65 years old with at least 50% scalp hair loss due to alopecia areata. The current episode of hair loss must have lasted at least 6 months and no longer than 10 years. The total time a person has had alopecia areata may exceed 10 years. Following a 24-week treatment period, participants will have the opportunity to enroll into an open-label extension study in which all participants will receive an active dose of CTP-543.

The THRIVE Clinical Program is being conducted at multiple research study centers throughout the United States and Canada. For more information about this important clinical research study, please visit our study website.

CTP-543 is a selective Janus kinase (JAK) inhibitor intended to disrupt the process that causes hair follicles to be incorrectly targeted by the body’s immune system. There are currently no FDA-approved treatments for alopecia areata.

US Thrive Clinical Program Website:

Canadian Thrive Clinical Program Website:

About The Patient Recruiting Agency™

Located in Austin, Texas, The Patient Recruiting Agency™ (TPRA) supports Sponsors, CROs, SMOs, and Investigators with patient recruitment services.


The Patient Recruiting Agency
Carl Wibbenmeyer